Advances in Post-Covalent Bruton`s Tyrosine Kinase Inhibitor Therapy for Relapsed/Refractory Chronic Lymphocytic Leukemia - report from EHA2025

27/06/2025 4 min

Listen "Advances in Post-Covalent Bruton`s Tyrosine Kinase Inhibitor Therapy for Relapsed/Refractory Chronic Lymphocytic Leukemia - report from EHA2025"

Episode Synopsis

Professor Matthew Davids shares his insights on the advances in post-covalent Bruton`s tyrosine kinase inhibitor therapy for relapsed/refractory chronic lymphocytic leukemia at the 2025 EHA Annual Meeting.Video: https://medicaldigest.org/scientific-contents/interview:advances-post-covalent-brutons-tyrosine-kinase-inhibitor-therapy-relapsedrefractory-chronic-lymphocytic-leukemia

More episodes of the podcast Medical Digest & Congress Report